Key Trends and Insights into the Dravet Syndrome Market: Growth Rate and Opportunities to 2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the dravet syndrome market grown in recent years?
The market size for Dravet Syndrome has seen considerable growth in recent times, and it is expected to further expand from $0.37 billion in 2024 to $0.40 billion in 2025, with a compound annual growth rate (CAGR) of 9.0%. The growth recorded in the past period can be credited to a surge in the incidence of Dravet Syndrome, improved diagnosis rates owing to enhanced screening programs, more fund allocation to epilepsy research, regulatory encouragements for rare disease drugs, and an increased acceptance of treatments based on cannabis.
How is the dravet syndrome market size expected to evolve during the forecast period?
The market size for Dravet syndrome is set for substantial expansion in the coming years, with projections indicating a growth to $0.56 billion by 2029, at a Compound Annual Growth Rate (CAGR) of 8.7%. This predicted growth within the forecasted period can be credited to factors such as broader insurance coverage for rare ailments, escalating patient advocacy initiatives, enhanced affordability of genetic testing, more robust government backing for treating rare diseases, and increased access to specialized neurology clinics. Key trends anticipated during the forecast period encompass progress in gene therapy for seizure management, greater utilization of AI for preliminary diagnosis, precision medicine advancements for tailored treatment, innovation in epilepsy management drug delivery systems, and the growth of telehealth for monitoring patients remotely.
Get your dravet syndrome market report here!
https://www.thebusinessresearchcompany.com/report/dravet-syndrome-global-market-report
Which key drivers are propelling the dravet syndrome market’s growth?
The increasing incidence of neurological disorders is anticipated to boost the dravet syndrome market’s expansion. These disorders encompass a wide spectrum of ailments that impact the brain, spinal cord, and nervous system, resulting in movement, cognition, sensation, or other bodily function impairments. The rise in neurological disorders can be attributed to an aging population, lifestyle alterations, environmental influences, enhanced diagnostics, and escalating cases of neuroinfections and autoimmune diseases. Dravet syndrome contributes significantly to the understanding of neurological disorders through the progression of research on genetic mutations, brain excitability, and targeted treatments, potentially benefiting a wide range of neurological conditions. As an example, in April 2022, the Belgium-based European Brain Council, a non-profit entity, reported that over 600 neurological diseases and around 300 psychiatric conditions plague millions worldwide, including 65 million people with epilepsy. In Europe, 10.5 million individuals are suffering from dementia, with projections pointing to an increase to 18.7 million by 2050. Consequently, the growing incidence of neurological disorders is spurring the growth of the dravet syndrome market.
What are the market segments in the dravet syndrome industry?
The dravet syndrome market covered in this report is segmented –
1) By Treatment And Management: Seizure Medications, Ketogenic Diet, Vagus Nerve Stimulation, Other Treatments And Management
2) By Diagnosis: Magnetic Resonance Imaging Testing, Electroencephalography Testing, Sodium Voltage-Gated Channel Alpha Subunit 1 Testing, Other Diagnosis
3) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration
4) By End-user: Pharmaceutical Companies, Hospitals, Diagnostic Laboratories, Academic And Research Institutes, Other End-users
Subsegments:
1) By Seizure Medications: Anticonvulsants, Benzodiazepines, Levetiracetam, Cannabidiol (CBD) based medications, Topiramate, Lamotrigine
2) By Ketogenic Diet: Standard Ketogenic Diet (SKD), Modified Atkins Diet (MAD), Low Glycemic Index Treatment (LGIT), MCT (Medium Chain Triglyceride) Diet
3) By Vagus Nerve Stimulation: Implantable Vagus Nerve Stimulator (VNS), Non-invasive Vagus Nerve Stimulation (NIVNS), Adjunct Therapy With VNS For Seizure Control
4) By Other Treatments and Management: Physical and Occupational Therapy, Speech Therapy, Epilepsy Surgery, Cognitive Behavioral Therapy (CBT), Genetic Counseling And Support
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21175&type=smp
Which leading companies are shaping the growth of the dravet syndrome market?
Major companies operating in the dravet syndrome market are Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, H. Lundbeck A/S, BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Supernus Pharmaceuticals Inc., Zogenix Inc., Biocodex S.A., Encoded Therapeutics Inc., Marinus Pharmaceuticals Inc., Arvelle Therapeutics GmbH, Stoke Therapeutics Inc., Longboard Pharmaceuticals Inc., Xenon Pharmaceuticals Inc., Aeovian Pharmaceuticals Inc., GW Pharmaceuticals plc, Ovid Therapeutics Inc.
What key trends are currently impacting the dravet syndrome market’s development?
Primary businesses involved in the Dravet syndrome market are investing in the progression of precision medicine such as RNA-based therapies, aiming to create specific treatments that target the core genetic alterations related to Dravet syndrome. Such precision therapies aim to enhance treatment efficiency and decrease associated side effects. RNA-based therapies utilize RNA molecules to adjust gene manifestation or protein synthesis, allowing for the treatment of genetic conditions by tackling their root causes on the molecular scale. For instance, Stoke Therapeutics Inc., a biotech company based in the US, achieved U.S. Food and Drug Administration (FDA) approval in December 2024 for zorevunersen, a drug developed to treat dravet syndrome. This drug has been designed to amplify the expression of SCN1A gene which is commonly mutated in Dravet syndrome patients, focusing on correcting the core genetic issue rather than just controlling the symptoms. The resultant therapy employs RNA-based precision medicine to return proper neuron function, which could potentially lead to a reduction in seizure incidences and enhancement of cognitive results.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21175
Which geographic areas are influencing the growth of the dravet syndrome market?
North America was the largest region in the dravet syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dravet syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Cell and Gene Therapy Manufacturing Services Global Market Report 2025
Cell And Gene Therapy Supply Chain/Logistics Global Market Report 2025
Global Biosimilar Hormones Global Market Report 2025
https://thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
